杨谨, 医学博士，肿瘤学博士研究生导师,主任医师，教授，西安交通大学第一医院肿瘤内科副主任，肿瘤学系副主任。
研究领域（方向）
（1）乳腺癌基础和临床研究
（2）乳腺癌干细胞样特性与免疫微环境
个人及工作简历
杨谨，女，52岁，医学博士，主任医师，教授，肿瘤学博士研究生导师, 西安交通大学第一医院肿瘤内科副主任，肿瘤学系副主任。
1993年毕业于西安医科大学临床医疗系，2000年获西安交通大学肿瘤学硕士学位，2006年获医学博士学位。2010年美国马里兰大学Marlene and Stewart Greenbaum肿瘤中心访问学者。2016年哈佛大学医学院研修项目组人员。现任中国研究型医院学会乳腺癌专业委员会常委，中国女医师协会临床肿瘤专委会常委，中国临床肿瘤专业委员会（CSCO）乳腺癌专业委员会委员，中国医师学会肿瘤分会乳腺专业委员会委员，中国抗癌协会乳腺癌专业委员会委员，国家肿瘤质控中心乳腺癌专业委员会委员，国家肿瘤质控中心抗肿瘤药物监测专委会委员，中国抗癌协会肿瘤整合心脏专委会委员，中国抗癌协会肿瘤标志物专委会乳腺学组副主任委员，中国研究型医院学会精准医学与肿瘤MDT专委会乳腺学组副组长，中华医学会陕西医学会肿瘤内科分会常务委员，陕西省抗癌协会抗癌药物专业委员会主任委员，陕西省抗癌协会生物治疗专业委员会侯任主委，陕西省抗癌协会化疗专业委员会副主任委员，陕西省五一巾帼标兵，国家自然科学基金一审评委，《西安交通大学学报医学版》编委，《BMC Cancer》等国际杂志等特约审稿专家。近年发表论文50余篇，SCI收录47篇，副主编、参编医学专著7部，主持国家自然科学基金面上4项，主持陕西省国际合作、自然科学基金和科技攻关项目3项，参与国家科技重大专项-重大新药创制1项，获得陕西省科技进步奖2项，高校科技进步奖2项，院级临床研究重点项目1项，教改重点项目1项，主持院级新医疗、新技术2项。
科研项目
1.Amot-p130通过PTEN/Cdc42轴影响细胞外基质重构抑制乳腺癌侵袭转移的机制研究。No.82173277。国家自然科学基金面上项目，2022.01-2025.12。（主持人）
2.Angiomotin通过Hippo-YAP信号通路调控肾癌干细胞样特性的机制研究。No. 81572527。国家自然科学基金面上项目，2016.01-2020.12。（主持人）
3.Angiomotin与乳腺癌干细胞的关系。No.2015JM8406。陕西省自然科学基金，2016.01-2019.12。（主持人）
4.Angiomotin与乳腺癌内分泌耐药的关系及其作用机制。横向课题，2016.01-2019.12。（主持人）
5.肿瘤靶向纳米热疗中热质传输机理研究。No.2020GXLH-Y-018。陕西省重点研发计划-高校联合项目，2021.01-2023.12(共同主持)
6.基于患者基因组特征和PDO模型药敏的难治性HER2阳性晚期乳腺癌的精准靶向治疗研究。No.XJTU1AF-CRF-2020-006。西安交通大学第一医院临床研究重点项目，2021.01-2023.12(主持人)
7.西北地区恶性肿瘤新药临床评价示范性技术平台建设。No.2020ZX09201020。国家科技部重大新药创制科技重大专项，2020.01-2022.12(第二)
8.长链非编码RNA介导Amot亚型转换调控三阴性乳腺癌的侵袭转移及其机制研究。No. 2019KW-033陕西省国际合作项目，10.0万元，2020,01-2023,01. （主持人）
学术及科研成果、专利、论文
1. 细胞极性蛋白异常在癌症恶性进程中的作用机制研究。2017陕西省科学技术奖（二等奖）
2. 细胞极性蛋白异常在乳腺癌恶性进程中的作用机制研究。2017陕西高等学校科学技术奖（二等奖）
3. 肾癌特异性蛋白标志物的筛选、异常表达的分子机制和潜在靶向治疗价值。2019陕西省科学技术奖（三等奖）
4. 肾癌特异性蛋白标志物的筛选、异常表达的分子机制和潜在靶向治疗价值。2018陕西高等学校科学技术奖（二等奖）
5. Shen Yanwei, Li Shuting, Wang Xin, Wang Mengying, Tian Qi, Yang Jiao, Wang Jichang, Wang Biyuan, Liu Peijun, Yang Jin*.Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.J Exp Clin Cancer Res. 2019, 28;38(1):427.(SCI,IF:11.161)
6. Wang Fan, Liang Rui, Tandon N,H19X-encoded miR-424(322)/-503 cluster: emerging roles in cell differentiation, proliferation, plasticity and metabolism.Cell Mol Life Sci. 2018 Nov 24. doi: 10.1007/s00018-018-2971-0. Review.(SCI,IF: 9.261)
7. Tian Qi, Gao Huan, Zhou Yan, Zhu Lizhe, Yang Jiao, Wang Bo, Liu Peijun, Yang Jin*. RICH1 inhibits breast cancer stem cell traits through activating kinases cascade of Hippo signaling by competing with Merlin for binding to Amot-p80. Cell Death Dis. 2022,13(1):71. (通讯作者)（SCI, IF: 8.469）
8. Yang Jiao, Zhang Xiaoman, Chen Zheling,Shen Yanwei, Wang Fan, Wang Yaochun, Liu Yu, Liu Peijun, Yang Jin*.Angiomotin-p130 inhibits β-catenin stability by competing with Axin for binding to tankyrase in breast cancer.Cell Death Dis. 2019;10(3):179.（SCI, IF: 8.469）
9. Mao X, Li P, Wang Y ,Yang J*.CRB3 regulates contact inhibition by activating the Hippo pathway in mammary epithelial cells.Cell Death Dis. 2017,12;8(1):e2546. (通讯作者)（SCI, IF: 8.469）
10. Tian Qi, Zhou Yan, Zhu Lizhe, Gao Huan, Yang Jin*. Development and Validation of a Ferroptosis-Related Gene Signature for Overall Survival Prediction in Lung Adenocarcinoma. Front Cell Dev Biol. 2021,9:684259. (通讯作者)（SCI, IF: 6.684）
11. Meng Lv, Yanwei Shen, Jiao Yang, Shuting Li, Biyuan Wang, Zheling Chen, Pan Li, Peijun Liu, Jin Yang. Angiomotin family members: oncogenes or tumor suppressors? International Journal of Biological Sciences. 2017 ;13(6):772-781. (SCI,IF: 6.582)
12. Gao Huan, Tian Qi, Zhu Lizhe, Feng Jinteng, Zhou Yan, Yang Jin*. 3D Extracellular Matrix Regulates the Activity of T Cells and Cancer Associated Fibroblasts in Breast Cancer. Front Oncol. 2021, 11:764204. (通讯作者)（SCI, IF: 6.244）
13. Wang Y, Liu S, Zhang Y, Yang J .Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype.Front Oncol. 2020 Apr 30;10:547. (SCI,IF:6.244)
14. Chen ZL, Yang J, Shen YW, Li ST, Wang X, Lv M, Wang BY, Li P, Zhao W, Qiu RY, Liu Y, Liu PJ, Yang J.AmotP130 regulates Rho GTPase and decreases breast cancer cell mobility.J Cell Mol Med. 2018 Apr;22(4):2390-2403. (SCI,IF：5.310)
15. Shen Y, Quan J, Wang M, Li S, Yang J, Lv M, Chen Z, Zhang L, Zhao X, Yang J.Tumor vasculogenic mimicry formation as an unfavorable prognostic indicator in pati：ents with breast cancer.Oncotarget. 2017, 7;8(34):56408-56416. (通讯作者) (SCI，IF:5.168 )
16. Li S, Shen Y, Wang M, Yang J, Lv M, Li P, Chen Z, Yang J.Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.Oncotarget. 2017 9;8(19):32043-32054. (通讯作者) (SCI，IF:5.168)
17. Chen Z, Ren Y, Du XL, Yang J, Shen Y, Li S, Wu Y, Lv M, Dong D, Li E, Li W, Liu P, Yang J, Yi M.Incidence and survival differences in esophageal cancer among ethnic groups in the United States.Oncotarget. 2017,18;8(29):47037-47051 (通讯作者) (SCI，IF: 5.168)
18. Lv Meng,Li Shuting,Luo changqin,Yang J* Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP. Oncotarget. 2016 ,15;7(11):12393-403. (通讯作者) (SCI，IF: 5.168)
19. Zhang Pengfei, Shao Yuan, Quan Fang, Liu Lifeng, Yang Jin*. FBP1 enhances the radiosensitivity by suppressing glycolysis via the FBXW7/mTOR axis in nasopharyngeal carcinoma cells. Life Sci. 2021,283:119840. (通讯作者)（SCI, IF: 5.037）
20. Wang Fan, Liang Rui, Soibam B, Yang Jin, Liu Yu.Coregulatory long non-coding RNA and protein-coding genes in serum starved cells.Biochim Biophys Acta Gene Regul Mech. 2019 Jan;1862(1):84-95. (SCI,IF:4.490)
21. Zhang Mi, Wang Biyuan, Liu Na, Wang Hui, Zhang Juan, Wu Lei, Zhao Andi, Wang Le, Zhao Xiaoai, Yang Jin*. Nomogram for predicting preoperative regional lymph nodes metastasis in patients with metaplastic breast cancer: a SEER population-based study. BMC Cancer. 2021,21(1):565. (通讯作者)（SCI, IF: 4.430）
22. Wang Biyuan, Wang Hui, Zhao Andi, Zhang Mi, Yang Jin*. Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits. BMC Cancer. 2021,21(1):523. (通讯作者)（SCI, IF: 4.430）
23. Zhao W, Wu L, Zhao A, Zhang M, Tian Q, Shen Y, Wang F, Wang B, Wang L, Chen L, Zhao X, Dong D, Zhang L, Yang JA nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study.BMC Cancer. 2020 Oct 12;20(1):982. (SCI,IF:4.430)
24. Yang J, Du XL, Li S, Wu Y, Lv M, Dong D, Zhang L, Chen Z, Wang B, Wang F, Shen Y, Li E, Yi M, Yang J.The risk and survival outcome of subsequent primary colorectal cancer after the first primary colorectal cancer: cases from 1973 to 2012. BMC Cancer. 2017, 22;17(1):783. doi: 10.1186/s12885-017-3765-8. (通讯作者) (SCI，IF: 4.430)
25. Wang X, Shen Y, MengLv L, Zhang X, Yang J, Wang F, Yang J.Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice.Eur J Pharm Sci. 2020 Aug 1;151:105302. (SCI,IF:4.384)
26. Liu J,Li J,Li P,Wang Y,Liang Z,Jiang Y,Li J,Feng C,Wang R,Chen H,Zhou C,Zhang J,Yang J,Liu P. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.Sci Rep.2017 Feb 7;7:42125. (共同通讯作者) (SCI，IF: 4.380)
27. Zhang Juan, Tian Qi, Zhang Mi, Wang Hui, Wu Lei, Yang Jin*. Immune-related biomarkers in triple-negative breast cancer. Breast Cancer. 2021,8(4):792-805. (通讯作者)（SCI, IF: 4.239）
28. Zhao W, Tian Q, Zhao A, Wang B, Yang J, Wang L, Zhang L, Dong D, Chen L, Yang J.The role of adjuvant radiotherapy in patients with malignant phyllodes tumor of the breast: a propensity-score matching analysis.Breast Cancer. 2021 Jan;28(1):110-118. (SCI,IF:4.239)
29. Yang J, Li S, Lv M, Wu Y, Chen Z, Shen Y, Wang B, Chen L, Yi M, Yang J.Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study.Onco Targets Ther. 2017 ,13;10:1535-1548. (通讯作者) (SCI，IF: 4.147)
30. Shen YW, Zhang XM, li ST,Yang J*. Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. Oncotargets and Therapy, 2016:9 929–935. (通讯作者) (SCI，IF: 4.147)
31. Chen ZL, Shen YW, Li ST,Yang J*.The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.Onco Targets Ther. 2016 ,30;9:3233-47. (通讯作者) (SCI，IF: 4.147)
32. Wang X, Shen Y, Li S, Lv M, Zhang X, Yang J, Wang F, Yang J*.Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review).Int J Mol Med. 2016; 38(4):1021-1029. (通讯作者) (SCI，IF: 4.101)
33. Wang F, Dohogne Z, Yang J,.Predictors of breast cancer cell types and their prognostic power in breast cancer patients.BMC Genomics. 2018 Feb 13;19(1):137. (SCI,IF：3.969)
34. Zhang Pengfei, Tian Qi, Gao Huan, Zhao Andi, Shao Yuan, Yang Jin*. Inhibition of MAC30 exerts antitumor effects in nasopharyngeal carcinoma via affecting the Akt/GSK-3β/β-catenin pathway. J Biochem Mol Toxicol. 2022, Apr 4:e23061. (通讯作者)（SCI, IF: 3.652）
35. Yang J, Li S, Wang B, Wu Y, Chen Z, Lv M, Lin Y, Yang J*.Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Tumor Biol. 2016,37(9),11645-11655. (通讯作者) (SCI，IF: 3.650)
36. Zhao W, Wang B, Zhao A, et al.The role of radiotherapy in patients with resected ampullary carcinoma: findings based on SEER database.HPB (Oxford). 2019 May 2. pii: S1365-182X(19)30495-2. doi: 10.1016/j.hpb.2019.03.369. (SCI,IF:3.647)
37. Qiu R, Zhao W, Yang J, Shen Y, Wang B, Li P, Zhao A, Tian Q, Zhang M, Yi M, Yang J, Dong D.Comparative Analysis of Outcomes and Clinicopathological Characteristics of Synchronous and Metachronous Contralateral Breast Cancer: A Study of the SEER Database..J Breast Cancer. 2019, 3;22(2):297-310. (SCI,IF: 3.588)
38. Li S, Wang X, Yang J, Lv M, Zhang X, Li C, Zhang L, Shen Y, Zhang X, Chen Z, Wang F, Wang X, Li D, Yi M, Yang J.Clinicopathological features and survival of early stage breast cancer in northwest China: A population-based retrospective study of 1287 patients.Thorac Cancer. 2018 Jan;9(1):10-18.（SCI，IF：3.500）
39. Tian Qi, Gao Huan, Zhao Wen, Zhou Yan, Yang Jin*. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma. Future Oncol. 2021,17(31):4115-4129. (通讯作者)（SCI, IF: 3.404）
40. Li S, Yang J, Shen Y, Zhao X, Zhang L, Wang B, Li P, Wang Y, Yi M, Yang JClinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database..BMC Public Health. 2019 Nov 29;19(1):1592. (SCI,IF:3.295)
41. Chen Z, Yang J, Li S, Lv M, Shen Y, Wang B, Li P, Yi M, Zhao X, Zhang L, Wang L, Yang J.Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.PLoS One. 2017 ;12(9):e0182397. (通讯作者) (SCI，IF:3.240)
42. Wang B, Yang J, Li S, Lv M, Chen Z, Li E, Yi M, Yang J.Tumor location as a novel high risk parameter for stage II colorectal cancers.PLoS One. 2017,23;12(6):e0179910. (通讯作者) (SCI,IF: 3.240)
43. Li D, Du XL, Ren Y,Yang J*Comparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial Cancer.PLoS One. 2016 ,31;11(5):e0156617. (通讯作者)（SCI, IF: 3.240）
44. Yang J, Du XL, Li ST, et al.Characteristics of Differently Located Colorectal Cancers Support Proximal and Distal Classification: A Population-Based Study of 57,847 Patients.PLoS One. 2016 Dec 9;11(12):e0167540. (通讯作者)（SCI, IF: 3.240）
45. Zhao W, Qiu R, Li P, Yang J.PIM1: a promising target in patients with triple-negative breast cancer.Med Oncol. 2017 ;34(8):142. (通讯作者) (SCI，IF: 3.064)
46. Li Dan, Shen Yanwei, Ren Hui, Wang Li, Yang Jin*, Wang Yuan*. Angiomotin-p130 inhibits vasculogenic mimicry formation of small cell lung cancer independently of Smad2/3 signal pathway. J Bioenerg Biomembr. 2021,53(3):295-305. (共同通讯作者)（SCI, IF: 2.945）
47. Lv M, Zhang X, Shen Y, Wang F, Yang J, Wang B, Chen Z, Li P, Zhang X, Li S, Yang J.Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors.Medicine (Baltimore). 2017 ;96(17):e6799. (通讯作者) (SCI，IF: 1.889)
48. Wang F, Zhang XM, Shen YW, Li ST, Lv M, Li CL, Yang J, Chen ZL, Yang J*.Primary primitive neuroectodermal tumor in pelvicavity: an unusual case and literature review. Int J Clin Exp Med, 2016;9(2):4767-4774. (通讯作者) (SCI，IF: 0.166)
联系方式
电子邮箱：1473106133@qq.com
联系电话：18991232383
联系地址：西安交通大学第一医院肿瘤内科
